1. Clinical & Scientific Overview
Enoxaparin Sodium (TIP-MED-000280, Reference Code [3.44]-C10) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a High-Alert P2Y12 Antiplatelets, Direct Thrombin Inhibitor & Low-Molecular-Weight Heparin (Schedule H | HIGH-ALERT).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [3.44] (Ticagrelor, Prasugrel, Dabigatran Etexilate & Enoxaparin Sodium). Representative Indian Market Examples (Edition 2.7 Ch 03 [3.44], p. 42): Ticagrelor: Brilinta (AstraZeneca), Axcer (Sun). Prasugrel: Effient, Prasita. Dabigatran: Pradaxa (Boehringer), Dabipla. Enoxaparin: Clexane (Sanofi), Lonopin (Biocon) — Strengths & Dosage Forms: Ticagrelor: 60 mg, 90 mg. Prasugrel: 5 mg, 10 mg. Dabigatran Capsules: 75 mg, 110 mg, 150 mg. Enoxaparin Pre-Filled Syringes: 20 mg/0.2mL, 40 mg/0.4mL, 60 mg/0.6mL
Ticagrelor: 60 mg, 90 mg. Prasugrel: 5 mg, 10 mg. Dabigatran Capsules: 75 mg, 110 mg, 150 mg. Enoxaparin Pre-Filled Syringes: 20 mg/0.2mL, 40 mg/0.4mL, 60 mg/0.6mL
3. Mechanism of Action & Pharmacodynamics
High-Alert P2Y12 Antiplatelets, Direct Thrombin Inhibitor & Low-Molecular-Weight Heparin (Schedule H | HIGH-ALERT) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via High-Alert P2Y12 Antiplatelets, Direct Thrombin Inhibitor & Low-Molecular-Weight Heparin (Schedule H | HIGH-ALERT) for Ticagrelor/Prasugrel: Acute Coronary Syndrome (ACS) & post-PCI stent DAPT with Aspirin 75 mg OD. Dabigatran: NVAF stroke prevention & DVT/PE. Enoxaparin: VTE prophylaxis/treatment & ACS.
4. Therapeutic Indications & Evidence-Supported Uses
- Ticagrelor/Prasugrel: Acute Coronary Syndrome (ACS) & post-PCI stent DAPT with Aspirin 75 mg OD
- Dabigatran: NVAF stroke prevention & DVT/PE
- Enoxaparin: VTE prophylaxis/treatment & ACS
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Ticagrelor: 180 mg load, then 90 mg BD x 12m (with Aspirin <=100 mg!). Prasugrel: 60 mg load, then 10 mg OD (5 mg OD if Wt <60 kg). Dabigatran: 150 mg BD (110 mg BD if Age >=80 yr, on Verapamil, or high bleed risk). Enoxaparin: Prophylaxis 40 mg SC OD; Treatment 1 mg/kg SC BD (1 mg/kg OD if CrCl <30)
Administration & Meal Timing: Swallow Dabigatran capsules WHOLE with a full glass of water — NEVER open, crush, or chew Dabigatran capsules (opening increases bioavailability by 75% and causes fatal bleeding!) | Ticagrelor & Dabigatran: Morning & Evening (12-hourly BD). Prasugrel: OD
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [3.44].
Renal: Dabigatran: 80% renally cleared — CONTRAINDICATED if CrCl <30 mL/min! Enoxaparin: If CrCl <30 mL/min, reduce treatment dose to 1 mg/kg SC OD (and prophylaxis to 20–30 mg OD)
Renal: Dabigatran: 80% renally cleared — CONTRAINDICATED if CrCl <30 mL/min! Enoxaparin: If CrCl <30 mL/min, reduce treatment dose to 1 mg/kg SC OD (and prophylaxis to 20–30 mg OD)
Renal: Dabigatran: 80% renally cleared — CONTRAINDICATED if CrCl <30 mL/min! Enoxaparin: If CrCl <30 mL/min, reduce treatment dose to 1 mg/kg SC OD (and prophylaxis to 20–30 mg OD)
7. Contraindications, Precautions & High-Risk Warnings
- CONTRAINDICATIONS: Active bleeding, history of intracranial haemorrhage. Prasugrel: Contraindicated in prior Stroke/TIA (boxed warning!) and discouraged if Age >=75 yr. Dabigatran: Contraindicated in mechanical heart valves, rheumatic mitral stenosis, and CrCl <30 mL/min! Ticagrelor: Contraindicated with Aspirin >100 mg/d, severe hepatic impairment, or strong CYP3A4 inhibitors
Key Clinical Precautions: Renal: Dabigatran: 80% renally cleared — CONTRAINDICATED if CrCl <30 mL/min! Enoxaparin: If CrCl <30 mL/min, reduce treatment dose to 1 mg/kg SC OD (and prophylaxis to 20–30 mg OD)
8. Adverse Effects Profile
- Easy bruising, epistaxis, dyspepsia (Dabigatran capsules contain tartaric acid core -> 10% GI upset), transient dyspnoea (Ticagrelor — 10–14% due to adenosine uptake inhibition), injection-site ecchymosis (Enoxaparin)
- Major GI or intracranial haemorrhage, acute coronary stent thrombosis if DAPT stopped early, heparin-induced thrombocytopenia (HIT — Enoxaparin), spinal/epidural haematoma
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Ticagrelor + Clarithromycin/Itraconazole = contraindicated; Ticagrelor increases Digoxin & Simvastatin (>40 mg)
- Dabigatran + Dronedarone/Ketoconazole/Rifampicin = contraindicated; Verapamil/Amiodarone increase Dabigatran
- Avoid NSAIDs with all agents!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [3.44].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: CRITICAL COUNTER WARNINGS: (1) Never stop Brilinta/Prasita after heart stent without cardiologist approval; (2) Never open Pradaxa capsules or remove them from their foil blister into a plastic pillbox; (3) For Clexane syringe: do NOT expel the air bubble before injecting into abdominal fat fold!
- Meal & Clock Timing Instruction: Swallow Dabigatran capsules WHOLE with a full glass of water — NEVER open, crush, or chew Dabigatran capsules (opening increases bioavailability by 75% and causes fatal bleeding!) (Ticagrelor & Dabigatran: Morning & Evening (12-hourly BD). Prasugrel: OD)
- Missed Dose Protocol: BD agents: Take within 6h; OD agents: Same day; never double dose
- Geriatric Dispensing Pearl: In patients >=75–80 years: Avoid Prasugrel; use Dabigatran 110 mg BD (or prefer Apixaban in elderly CKD); adjust Enoxaparin for CrCl <30 mL/min
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ticagrelor: 60 mg, 90 mg. Prasugrel: 5 mg, 10 mg. Dabigatran Capsules: 75 mg, 110 mg, 150 mg. Enoxaparin Pre-Filled Syringes: 20 mg/0.2mL, 40 mg/0.4mL, 60 mg/0.6mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.